STOCK TITAN

Denali Therapeutics (DNLI) Stock Price, News & Analysis

DNLI NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
32 252 sessions, November 19, 2025 to November 19, 2026
Largest daily move
-14.5% close of July 14, 2026
1-year change
+7.6% closing prices, November 19, 2025 to November 19, 2026
1-month change
+0.9% closing prices, October 19, 2026 to November 19, 2026

Company Description

Denali Therapeutics Inc. (NASDAQ: DNLI) is a biotechnology and biopharmaceutical company focused on developing product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases, lysosomal storage diseases and other serious conditions. According to company disclosures, Denali is based in South San Francisco, California and trades on the Nasdaq under the symbol DNLI. The company describes itself as pioneering a new class of biotherapeutics designed to reach the brain using its proprietary TransportVehicle™ (TV) platform.

Core focus and therapeutic areas

Denali’s stated goal is to deliver effective medicines for people living with neurodegenerative diseases, lysosomal storage diseases and other serious diseases. Its work includes programs in Hunter syndrome (mucopolysaccharidosis type II, or MPS II), Sanfilippo syndrome type A (MPS IIIA), granulin-related frontotemporal dementia (FTD-GRN), Parkinson’s disease, Alzheimer’s disease, Pompe disease, Gaucher disease and MPS I, among others. The company reports that it rigorously assesses genetically validated targets, engineers delivery across the BBB and uses biomarkers to demonstrate target and pathway engagement.

TransportVehicle™ platform and blood-brain barrier delivery

A central element of Denali’s business is its TransportVehicle™ (TV) platform, which it describes as a proprietary technology designed to deliver large therapeutic molecules throughout the body, including the brain, by crossing the BBB after intravenous administration. The platform is based on engineered Fc domains that bind to natural transport receptors such as the transferrin receptor and CD98 heavy chain amino acid transporter, which are expressed at the BBB. Through receptor-mediated transcytosis, these engineered molecules can transport therapeutic cargo into the brain.

Denali reports that antibodies and enzymes engineered with the TV platform have shown more than 10- to 30-fold greater brain exposure in animal models compared with similar molecules without this technology, and that TV-enabled oligonucleotides have demonstrated more than a 1,000-fold greater brain exposure in primates than systemically delivered oligonucleotides without the platform. The company states that the TV platform has been clinically validated and that multiple TV-enabled programs are in clinical development.

Lead program: tividenofusp alfa (DNL310, ETV:IDS) for Hunter syndrome

Denali identifies tividenofusp alfa (DNL310) as its lead investigational enzyme replacement therapy for Hunter syndrome (MPS II). Tividenofusp alfa is composed of the iduronate 2‑sulfatase (IDS) enzyme fused to the TV platform and is designed to deliver IDS into both the brain and the body, with the goal of addressing behavioral, cognitive and physical symptoms of MPS II. The U.S. Food and Drug Administration (FDA) has granted Fast Track, Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations to tividenofusp alfa, and the European Medicines Agency has granted Priority Medicines designation, according to company press releases.

Denali reports results from an open-label Phase 1/2 study of tividenofusp alfa in children with MPS II, including reductions and normalization in key disease biomarkers, normalization of liver volume, improvement in hearing thresholds and skill gains on measures of adaptive behavior and cognition. The company states that the most common treatment-related adverse events were infusion-related reactions that decreased with continued use. A Biologics License Application (BLA) for tividenofusp alfa for MPS II is under FDA Priority Review, with a Prescription Drug User Fee Act (PDUFA) target action date of April 5, 2026, as disclosed in multiple news releases and related SEC filings. Denali is conducting the global Phase 2/3 COMPASS study in participants with MPS II in North America, South America and Europe to generate confirmatory evidence and support global regulatory submissions.

Additional TV-enabled lysosomal storage disease programs

Beyond Hunter syndrome, Denali highlights several TV-enabled programs targeting other lysosomal storage disorders:

  • DNL126 (ETV:SGSH) for Sanfilippo syndrome type A (MPS IIIA): An enzyme TransportVehicle (ETV) program for MPS IIIA. Denali reports that an ongoing Phase 1/2 study has completed enrollment and that cerebrospinal fluid heparan sulfate has been aligned with the FDA as a reasonably likely surrogate endpoint to support an accelerated approval path. Planning for a global Phase 3 confirmatory study is described as ongoing.
  • DNL952 (ETV:GAA) for Pompe disease: An ETV-enabled program designed to enhance delivery of the missing GAA enzyme into muscle tissues and across the BBB into the brain. Denali discloses that the FDA has lifted a clinical hold on the Investigational New Drug (IND) application for DNL952 and that the company plans to proceed with a Phase 1 study.
  • DNL111 (ETV:GCase) for Parkinson’s disease and Gaucher disease, DNL622 (ETV:IDUA) for MPS I: These are described as ETV programs in IND‑enabling stages, aimed at additional lysosomal storage and related disorders.

Neurodegenerative disease and oligonucleotide programs

Denali also reports a portfolio of programs in neurodegenerative diseases that use small molecules and TV-enabled oligonucleotides and antibodies:

  • BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease: A small molecule program co-developed with Biogen. The company states that the global Phase 2b LUMA study in early-stage Parkinson’s disease has completed enrollment, with a clinical readout expected in 2026, and that Denali’s Phase 2a BEACON study in LRRK2-associated Parkinson’s disease remains ongoing.
  • TAK‑594/DNL593 (PTV:PGRN) for GRN-related frontotemporal dementia (FTD‑GRN): A program developed in collaboration with Takeda, designed to deliver progranulin across the BBB for FTD‑GRN. Denali reports that a Phase 1/2 study is ongoing.
  • DNL628 (OTV:MAPT) for Alzheimer’s disease: An Oligonucleotide TransportVehicle™ (OTV) program designed to reduce tau protein by targeting the MAPT gene. Denali discloses that a Clinical Trial Application for a Phase 1b study has been approved and that study start-up activities are underway.
  • DNL921 (ATV:Abeta) for Alzheimer’s disease: An Antibody TransportVehicle (ATV) program in IND-enabling stage. Denali has reported preclinical data showing that TV-enabled anti‑amyloid beta antibodies improved brain distribution and affected amyloid-related imaging abnormalities in animal models.
  • DNL422 (OTV:SNCA) for Parkinson’s disease: An OTV program in IND‑enabling stage targeting the SNCA gene.

Collaborations and funding arrangements

Denali reports several collaborations with larger biopharmaceutical companies. It has active collaborations with Biogen for BIIB122/DNL151 in Parkinson’s disease and with Takeda for TAK‑594/DNL593 in FTD‑GRN, with 50/50 U.S. commercial rights described for these programs. The company also states that it is eligible to receive royalty payments for SAR443122/DNL758, a small molecule RIPK1 inhibitor licensed to Sanofi and in development for ulcerative colitis.

In addition, Denali and Royalty Pharma announced a synthetic royalty funding agreement based on future net sales of tividenofusp alfa. Under that agreement, Royalty Pharma agreed to make payments to Denali in exchange for a royalty on worldwide net sales of tividenofusp alfa, subject to specified caps and conditions, including regulatory approvals.

Business model and development stage

Based on its public statements, Denali operates as a clinical-stage biopharmaceutical company. It reports a broad portfolio of investigational product candidates across discovery, IND‑enabling, early-stage and late-stage clinical development. The company emphasizes its focus on genetically validated targets, BBB delivery engineering and biomarker-driven development. Denali’s revenue and expense details, as disclosed in quarterly financial results, reflect significant research and development spending and preparations for a potential commercial launch of tividenofusp alfa, but all of its drugs are described as investigational and not yet approved for any indication.

Regulatory and clinical development focus

Denali’s disclosures highlight its engagement with regulators such as the FDA and the European Medicines Agency. For MPS II and MPS IIIA, the company reports alignment on accelerated approval pathways using biomarkers like cerebrospinal fluid heparan sulfate as surrogate endpoints. For tividenofusp alfa, Denali notes that the FDA is conducting a Priority Review of its BLA under the accelerated approval pathway, with a defined PDUFA action date. The company also notes that the FDA extended the PDUFA date after Denali submitted updated clinical pharmacology information classified as a Major Amendment.

Capital markets activity

Denali’s SEC filings and press releases describe capital-raising activities, including an underwritten public offering of common stock and pre-funded warrants and a registration statement on Form S‑3. The company has also disclosed its cash, cash equivalents and marketable securities balances in quarterly reports, along with net losses and operating expenses associated with its research and development and general and administrative activities.

Position within biotechnology and manufacturing sector

Within the broader biotechnology and manufacturing sector, Denali is classified under biological product manufacturing and describes itself as focused on BBB-crossing biotherapeutics. Its work spans enzyme replacement therapies, antibodies, oligonucleotides and small molecules, all oriented toward conditions where delivery to the brain and central nervous system is a key challenge. The company’s own descriptions emphasize that its TV platform is intended to address limitations of conventional therapies that do not adequately cross the BBB, particularly in rare lysosomal storage diseases and neurodegenerative disorders.

Risk and forward-looking considerations

Denali’s press releases and SEC filings include extensive cautionary statements regarding forward-looking information. The company notes that all of its product candidates are investigational and have not received regulatory approval, and that clinical development, regulatory review, manufacturing, collaborations and market conditions involve significant risks and uncertainties. Investors and other readers are directed in those documents to risk factors described in Denali’s annual and quarterly reports filed with the U.S. Securities and Exchange Commission.

Stock Performance

$18.20
+0.00%
+0.00
After hoursChange vs the $18.20 closeLast updated: at
+7.6%
Performance 1 year

Denali Therapeutics (DNLI) closed at $18.20 on November 19, 2026. Over the past 12 months, the price has gained 7.6%.

See what a $1,000 investment in DNLI would be worth today

Average down calculator for DNLI

DNLI Metrics & Rankings

Price returns through November 19, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Denali Therapeutics has 10 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 7 with negative movement. Key topics include earnings, earnings date. View all DNLI news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
15,861
Shares Sold
4
Transactions
Most Recent Transaction
Chin Peter Scott (Chief Medical Officer) sold 1,654 shares @ $22.29 on September 4, 2026

Insider selling at Denali Therapeutics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Denali Therapeutics reported operating income of -$555.3M in FY2025, and net income was -$512.5M. Diluted earnings per share stood at -$2.97. The company generated -$412.6M in operating cash flow. The current ratio was 9.16, measuring current assets divided by current liabilities.

$0
Revenue (FY2025)
-$512.5M
Net Income (FY2025)
-$412.6M
Operating Cash Flow

Upcoming Events

YEAR
2026
2026 Clinical

Phase 1/2 results release

Topline Phase 1/2 results with biomarker data expected; 40 FTD-GRN participants enrolled.
YEAR
2027
2027 Regulatory

BLA submission

Planned 2027 BLA submission for zafinofusp alfa in Sanfilippo syndrome type A; regulatory filing anticipated during 2027.
H1
2027
H1 2027 Clinical

Phase 2a BEACON readout

Topline Phase 2a BEACON data readout expected H1 2027 for LRRK2 carriers; Denali to announce timing, no webcast yet.
YEAR
2027
2027 Regulatory

Accelerated approval submission

Denali plans a 2027 submission seeking accelerated approval for zafinofusp alfa for Sanfilippo syndrome type A; regulatory filing target.
YEAR
2027
2027 Clinical

Phase 1/2 data readout

Denali expects additional Phase 1/2 clinical data in early 2027 for zafinofusp alfa; results may inform regulatory strategy and commercialization.
YEAR
2027
2027 Clinical

TransportVehicle data readouts

Five TransportVehicle programs are expected to generate data during 2027; multiple program readouts could affect pipeline valuation and partnering.
H1
2028
H1 2028 Clinical

COMPASS data readout

COMPASS confirmatory study enrollment complete; Denali expects top-line COMPASS data in H1 2028 to support potential regulatory decisions.
DEC
31
December 31, 2029 Regulatory

EMA approval deadline

Deadline for EMA approval that would trigger $75M payment from Royalty Pharma

Denali Therapeutics has 8 upcoming scheduled events. The next event, "Phase 1/2 results release", is expected in 2026. Investors can track these dates to stay informed about potential catalysts that may affect the DNLI stock price.

Short Interest History

Last 12 Months

Short interest in Denali Therapeutics (DNLI) currently stands at 14.7 million shares, down 5.0% from the previous reporting period, representing 9.7% of the float. Since November 2025, short interest has increased by 13.2%.

Days to Cover History

Last 12 Months

Days to cover for Denali Therapeutics (DNLI) currently stands at 9.9 days, up 22.8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 6.2 to 17.5 days.

DNLI Company Profile & Sector Positioning

Denali Therapeutics (DNLI) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing DNLI often look at related companies in the same sector, including Dyne Therapeutics, Inc. (DYN), Viridian Therapeutics, Inc. (VRDN), Telix Pharmaceuticals Limited (TLX), MBX Biosciences, Inc. (MBX), and Disc Medicine, Inc. (IRON). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate DNLI's relative position within its industry.

Frequently Asked Questions

The current stock price of Denali Therapeutics (DNLI) is $18.20 in after-hours trading as of November 19, 2026.

The market cap of Denali Therapeutics (DNLI) is approximately $2.9B. Learn more about what market capitalization means .

The FY2025 revenue of Denali Therapeutics (DNLI) is $0, from its most recent completed fiscal year.

The FY2025 net income of Denali Therapeutics (DNLI) is -$512.5M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Denali Therapeutics (DNLI) is -$2.97 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Denali Therapeutics (DNLI) is -$412.6M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Denali Therapeutics (DNLI), current assets divided by current liabilities, was 9.16 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Denali Therapeutics (DNLI) is -$555.3M for FY2025, its most recent completed fiscal year. Learn about operating income.